Watchlist Price Alert

Ascendis Pharma A/S (ASND)

NASDAQ: ASND · Real-Time Price · USD

171.15

-0.91 (-0.53%)

At close: May 05, 2025, 3:59 PM

168.25

-1.69%

After-hours: May 05, 2025, 05:50 PM EDT

-0.53% (1D)

Bid	168.25
Market Cap	10.33B
Revenue (ttm)	368.7M
Net Income (ttm)	-341.67M
EPS (ttm)	-7.47
PE Ratio (ttm)	-22.91
Forward PE	141.22
Analyst	Buy

Ask	180
Volume	405,398
Avg. Volume (20D)	634,505.8
Open	175.19
Previous Close	172.06
Day's Range	169.44 - 175.38
52-Week Range	111.09 - 183.00
Beta	0.54

About ASND

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops Tra...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 28, 2015

Employees 1,017

Stock Exchange NASDAQ

Ticker Symbol ASND

Website https://ascendispharma.com

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for ASND stock is "Buy." The 12-month stock price forecast is $207, which is an increase of 20.95% from the latest price.

Stock Forecasts

Earnings Surprise

Ascendis Pharma A/S has released their quartely earnings on May 1, 2025:

Revenue of $106.16M exceeds estimates by $11.28M, with 1.94% YoY growth.

EPS of -1.66 misses estimates by -0.15, with 33.60% YoY growth.

Why Price Moved

2 months ago

+8.41%

Ascendis Pharma shares are trading higher after Ev... Unlock content with Pro Subscription

2 months ago

+12.96%

Ascendis Pharma shares are trading higher after the company reported better-than-expected Q4 financial results and authorized a share repurchase program worth $18.25 million.

News

4 days ago · seekingalpha.com

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Scott Smith - Executive Vice President and Chief Financial Officer Jan Mikkelsen - President and...

2 weeks ago · zacks.com

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

3 weeks ago · seekingalpha.com

Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory

Shares of ASND have fared well during recent market volatility and the downturn in the biotech sector. Setbacks for competitors in PTH (hypoparathyroidism) paves the way for successful Yorvipath launc...

3 weeks ago · accessnewswire.com

Ascendant Resources Notifies Shareholders Of Upcoming Special Meeting

TORONTO, ON / ACCESS Newswire / April 14, 2025 / Further to its press release on February 3, 2025, Ascendant Resources Inc. (the "Company" or "Ascendant") (TSX:ASND) announces that it has mailed and f...

1 month ago · zacks.com

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

2 months ago · benzinga.com

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?

On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.

2 months ago · seekingalpha.com

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Ch...

2 months ago · accessnewswire.com

Ascendant Resources Announces Closing of First Tranche of Private Placement

• Funds to Progress Lagoa Salgada Project and extinguish a significant portion of short-term payables • Additional Support Received for Arrangement with Cerrado NOT FOR DISTRIBUTION TO U.S. NEWS WIRE ...